Free Trial
NASDAQ:NXTC

NextCure (NXTC) Stock Price, News & Analysis

NextCure logo
$0.46 +0.01 (+3.29%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$0.46 +0.00 (+0.31%)
As of 07/8/2025 05:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About NextCure Stock (NASDAQ:NXTC)

Key Stats

Today's Range
$0.42
$0.48
50-Day Range
$0.38
$0.68
52-Week Range
$0.22
$1.82
Volume
94,400 shs
Average Volume
127,470 shs
Market Capitalization
$12.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.50
Consensus Rating
Buy

Company Overview

NextCure Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
84th Percentile Overall Score

NXTC MarketRank™: 

NextCure scored higher than 84% of companies evaluated by MarketBeat, and ranked 179th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    NextCure has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    NextCure has only been the subject of 1 research reports in the past 90 days.

  • Read more about NextCure's stock forecast and price target.
  • Earnings Growth

    Earnings for NextCure are expected to grow in the coming year, from ($1.87) to ($1.44) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of NextCure is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of NextCure is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    NextCure has a P/B Ratio of 0.19. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about NextCure's valuation and earnings.
  • Percentage of Shares Shorted

    1.22% of the float of NextCure has been sold short.
  • Short Interest Ratio / Days to Cover

    NextCure has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NextCure has recently increased by 266.67%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    NextCure does not currently pay a dividend.

  • Dividend Growth

    NextCure does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.22% of the float of NextCure has been sold short.
  • Short Interest Ratio / Days to Cover

    NextCure has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NextCure has recently increased by 266.67%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for NextCure this week, compared to 0 articles on an average week.
  • MarketBeat Follows

    1 people have added NextCure to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, NextCure insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.30% of the stock of NextCure is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    42.65% of the stock of NextCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about NextCure's insider trading history.
Receive NXTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NextCure and its competitors with MarketBeat's FREE daily newsletter.

NXTC Stock News Headlines

HC Wainwright Reaffirms Buy Rating for NextCure (NASDAQ:NXTC)
Trump’s Exec Order #14154 could be a “Millionaire-Maker”
Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape.
See More Headlines

NXTC Stock Analysis - Frequently Asked Questions

NextCure's stock was trading at $0.7710 on January 1st, 2025. Since then, NXTC shares have decreased by 40.9% and is now trading at $0.4556.

NextCure, Inc. (NASDAQ:NXTC) released its quarterly earnings results on Thursday, May, 1st. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.01.

NextCure (NXTC) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray served as the underwriters for the IPO.

Shares of NXTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that NextCure investors own include Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), AU Optronics (AUOTY), American Water Works (AWK), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR).

Company Calendar

Last Earnings
5/01/2025
Today
7/08/2025
Next Earnings (Estimated)
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NXTC
CIK
1661059
Fax
N/A
Employees
90
Year Founded
2015

Price Target and Rating

High Price Target
$4.00
Low Price Target
$3.00
Potential Upside/Downside
+668.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$55.65 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$2.34 per share
Price / Book
0.19

Miscellaneous

Free Float
24,319,000
Market Cap
$12.78 million
Optionable
Optionable
Beta
1.06
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:NXTC) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners